Trials / Withdrawn
WithdrawnNCT00505583
Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy
A Randomized, Double-Blind, Triple-Dummy, 3-Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Formulation of MOA-728 in Subjects on Stable Methadone Maintenance
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MOA-728 |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-07-23
- Last updated
- 2019-11-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00505583. Inclusion in this directory is not an endorsement.